Novartis Ag (NVSEF) Gains from Investment Securities (2009 - 2026)

Novartis Ag has disclosed Gains from Investment Securities across 16 years of filings, most recently posting -$787.0 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$787.0 million, down 45.74% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.8 billion (down 26.42% YoY), and the FY2025 annual result was -$981.0 million, changed N/A from the prior year.
• Gains from Investment Securities came in at -$787.0 million for Q1 2026 at Novartis Ag, up from -$981.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of -$260.0 million in Q3 2022 to a low of -$1.3 billion in Q4 2023.
• The 5-year median for Gains from Investment Securities is -$576.0 million (2024), against an average of -$611.9 million.
• Across the five-year window, Gains from Investment Securities surged 62.17% in 2022 and plunged 279.64% in 2023, its largest moves.
• Novartis Ag's Gains from Investment Securities stood at -$334.0 million in 2022, then slumped by 279.64% to -$1.3 billion in 2023, then rose by 27.13% to -$924.0 million in 2024, then fell by 6.17% to -$981.0 million in 2025, then grew by 19.78% to -$787.0 million in 2026.
• The last three Gains from Investment Securities figures came in at -$787.0 million (Q1 2026), -$981.0 million (Q4 2025), and -$366.0 million (Q3 2025), per Business Quant data.